brepocitinib vs Soficitinib (ICP-332)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: TYK2/JAK1 · full Psoriasis pipeline
brepocitinib · Lisraya
Marketed by Roivant Sciences Ltd. and partners
NCT02969018 · Phase 2 · completed
The trial randomized 212 participants to seven blinded PF-06700841 regimens or matching placebo, with PASI score change at week 12 as the clinical primary endpoint. Five of seven PF-06700841 regimens significantly improved PASI versus placebo, but two comparisons were not statistically significant, making the overall primary result mixed rather than consistently positive.
Reported efficacy
Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12 (Baseline (Day 1 pre-dose), Week 12): Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12 (Baseline (Day 1 pre-dose), Week 12): PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD -15.85 units on a scale (95% CI -18.31 to -13.39) | PF-06700841 60 mg QD Followed by 10 mg QD -10.56 units on a scale (95% CI -12.96 to -8.16) | PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW) -14.28 units on a scale (95% CI -16.75 to -11.81) | PF-06700841 60 mg QD Followed by Placebo -10.14 units on a scale (95% CI -12.62 to -7.66) | PF-06700841 30 mg QD -17.28 units on a scale (95% CI -19.55 to -15.02) | PF-06700841 30 mg QD Followed by 10 mg QD -13.27 units on a scale (95% CI -15.78 to -10.76) | PF-06700841 30 mg QD Followed by 100 mg QW -11.88 units on a scale (95% CI -14.16 to -9.59) vs Placebo -7.21 units on a scale (95% CI -9.96 to -4.46) (mixed)
Result source: NCT02969018
Soficitinib (ICP-332)
Developed by Beijing InnoCare Pharma Tech Co.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Psoriasis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | brepocitinib | Soficitinib (ICP-332) |
|---|---|---|
| PASI 75 | 36% vs 8.7%+27.3 vs placeboNCT02969018125 other results
| —Not reported |
| PASI 90 | 20% vs 4.3%+15.7 vs placeboNCT0296901862 other results
| —Not reported |
| PASI 100 | —Not reported | —Not reported |
| sPGA 0/1 | 11.4% vs 8.2%+3.2 vs placeboNCT0385048362 other results
| —Not reported |
| DLQI, change | —Not reported | —Not reported |
PASI 75
- brepocitinib
- 36% vs 8.7%+27.3 vs placeboNCT02969018
125 other results
- 10.3% vs 8.7% NCT02969018
- 30.8% vs 8.7% NCT02969018
- 20% vs 8.7% NCT02969018
- 48% vs 8.7% NCT02969018
- 17.2% vs 8.7% NCT02969018
- 34.6% vs 8.7% NCT02969018
- 16% vs 8.7% NCT02969018
- 60% vs 13% NCT02969018
- 24.1% vs 13% NCT02969018
- 57.7% vs 13% NCT02969018
- 24% vs 13% NCT02969018
- 48% vs 13% NCT02969018
- 24.1% vs 13% NCT02969018
- 61.5% vs 13% NCT02969018
- 32% vs 13% NCT02969018
- 60% vs 8.7% NCT02969018
- 37.9% vs 8.7% NCT02969018
- 65.4% vs 8.7% NCT02969018
- 32% vs 8.7% NCT02969018
- 44% vs 8.7% NCT02969018
- 41.4% vs 8.7% NCT02969018
- 65.4% vs 8.7% NCT02969018
- 36% vs 8.7% NCT02969018
- 24% vs 0% NCT02969018
- 41.4% vs 0% NCT02969018
- 61.5% vs 0% NCT02969018
- 36% vs 0% NCT02969018
- 8% vs 0% NCT02969018
- 13.8% vs 0% NCT02969018
- 26.9% vs 0% NCT02969018
- 12% vs 0% NCT02969018
- 0% vs 0% NCT02969018
- 6.9% vs 0% NCT02969018
- 7.7% vs 0% NCT02969018
- 4% vs 0% NCT02969018
- 58.6% vs 8.7% NCT02969018
- 12% vs 8.7% NCT02969018
- 16.7% vs 8.7% NCT02969018
- 75.9% vs 8.7% NCT02969018
- 16% vs 8.7% NCT02969018
- 16.7% vs 8.7% NCT02969018
- 86.2% vs 13% NCT02969018
- 24% vs 13% NCT02969018
- 36.7% vs 13% NCT02969018
- 72.4% vs 13% NCT02969018
- 28% vs 13% NCT02969018
- 46.7% vs 13% NCT02969018
- 65.5% vs 8.7% NCT02969018
- 20% vs 8.7% NCT02969018
- 40% vs 8.7% NCT02969018
- 51.7% vs 8.7% NCT02969018
- 28% vs 8.7% NCT02969018
- 26.7% vs 8.7% NCT02969018
- 27.6% vs 0% NCT02969018
- 24% vs 0% NCT02969018
- 36.7% vs 0% NCT02969018
- 3.4% vs 0% NCT02969018
- 8% vs 0% NCT02969018
- 0% vs 0% NCT02969018
- 0% vs 0% NCT02969018
- 4% vs 0% NCT02969018
- 0% vs 0% NCT02969018
- 11.1% vs 16.1% NCT03850483
- 17.4% vs 16.1% NCT03850483
- 25% vs 16.1% NCT03850483
- 15.4% vs 16.1% NCT03850483
- 13% vs 16.1% NCT03850483
- 12.5% vs 16.1% NCT03850483
- 15.4% vs 16.1% NCT03850483
- 7.7% vs 10.3% NCT03850483
- 8.7% vs 10.3% NCT03850483
- 21.4% vs 10.3% NCT03850483
- 14.3% vs 10.3% NCT03850483
- 13% vs 10.3% NCT03850483
- 20% vs 10.3% NCT03850483
- 14.8% vs 10.3% NCT03850483
- 10.3% vs 20.6% NCT03850483
- 7.7% vs 20.6% NCT03850483
- 20.7% vs 20.6% NCT03850483
- 17.9% vs 20.6% NCT03850483
- 12.5% vs 20.6% NCT03850483
- 24.1% vs 20.6% NCT03850483
- 17.9% vs 20.6% NCT03850483
- 3.3% vs 18.2% NCT03850483
- 8% vs 18.2% NCT03850483
- 17.2% vs 18.2% NCT03850483
- 14.3% vs 18.2% NCT03850483
- 20.8% vs 18.2% NCT03850483
- 10.7% vs 18.2% NCT03850483
- 15.4% vs 18.2% NCT03850483
- 6.7% vs 13.9% NCT03850483
- 7.4% vs 13.9% NCT03850483
- 6.5% vs 13.9% NCT03850483
- 14.3% vs 13.9% NCT03850483
- 16% vs 13.9% NCT03850483
- 13.8% vs 13.9% NCT03850483
- 14.3% vs 13.9% NCT03850483
- 0% vs 13.9% NCT03850483
- 7.4% vs 13.9% NCT03850483
- 6.5% vs 13.9% NCT03850483
- 10.3% vs 13.9% NCT03850483
- 10.7% vs 13.9% NCT03850483
- 10.7% vs 13.9% NCT03850483
- 10.3% vs 13.9% NCT03850483
- 0% vs 8.9% NCT03850483
- 3.6% vs 8.9% NCT03850483
- 0% vs 8.9% NCT03850483
- 0% vs 8.9% NCT03850483
- 6.7% vs 8.9% NCT03850483
- 3% vs 8.9% NCT03850483
- 12.1% vs 8.9% NCT03850483
- 0% vs 2.2% NCT03850483
- 0% vs 2.2% NCT03850483
- 2.9% vs 2.2% NCT03850483
- 0% vs 2.2% NCT03850483
- 0% vs 2.2% NCT03850483
- 6.3% vs 2.2% NCT03850483
- 5.7% vs 2.2% NCT03850483
- 3% vs 0% NCT03850483
- 0% vs 0% NCT03850483
- 0% vs 0% NCT03850483
- 0% vs 0% NCT03850483
- 0% vs 0% NCT03850483
- 2.9% vs 0% NCT03850483
- 2.7% vs 0% NCT03850483
- Soficitinib (ICP-332)
- —Not reported
PASI 90
- brepocitinib
- 20% vs 4.3%+15.7 vs placeboNCT02969018
62 other results
- 3.4% vs 4.3% NCT02969018
- 15.4% vs 4.3% NCT02969018
- 4% vs 4.3% NCT02969018
- 28% vs 4.3% NCT02969018
- 13.8% vs 4.3% NCT02969018
- 11.5% vs 4.3% NCT02969018
- 8% vs 4.3% NCT02969018
- 36% vs 4.3% NCT02969018
- 13.8% vs 4.3% NCT02969018
- 26.9% vs 4.3% NCT02969018
- 8% vs 4.3% NCT02969018
- 28% vs 4.3% NCT02969018
- 17.2% vs 4.3% NCT02969018
- 26.9% vs 4.3% NCT02969018
- 8% vs 4.3% NCT02969018
- 24% vs 0% NCT02969018
- 17.2% vs 0% NCT02969018
- 30.8% vs 0% NCT02969018
- 8% vs 0% NCT02969018
- 16% vs 0% NCT02969018
- 20.7% vs 0% NCT02969018
- 26.9% vs 0% NCT02969018
- 12% vs 0% NCT02969018
- 12% vs 0% NCT02969018
- 20.7% vs 0% NCT02969018
- 42.3% vs 0% NCT02969018
- 16% vs 0% NCT02969018
- 0% vs 0% NCT02969018
- 3.4% vs 0% NCT02969018
- 7.7% vs 0% NCT02969018
- 0% vs 0% NCT02969018
- 0% vs 0% NCT02969018
- 3.4% vs 0% NCT02969018
- 0% vs 0% NCT02969018
- 0% vs 0% NCT02969018
- 27.6% vs 4.3% NCT02969018
- 8% vs 4.3% NCT02969018
- 10% vs 4.3% NCT02969018
- 37.9% vs 4.3% NCT02969018
- 4% vs 4.3% NCT02969018
- 13.3% vs 4.3% NCT02969018
- 51.7% vs 4.3% NCT02969018
- 8% vs 4.3% NCT02969018
- 10% vs 4.3% NCT02969018
- 34.5% vs 4.3% NCT02969018
- 8% vs 4.3% NCT02969018
- 13.3% vs 4.3% NCT02969018
- 34.5% vs 0% NCT02969018
- 4% vs 0% NCT02969018
- 16.7% vs 0% NCT02969018
- 24.1% vs 0% NCT02969018
- 8% vs 0% NCT02969018
- 20% vs 0% NCT02969018
- 6.9% vs 0% NCT02969018
- 8% vs 0% NCT02969018
- 3.3% vs 0% NCT02969018
- 0% vs 0% NCT02969018
- 0% vs 0% NCT02969018
- 0% vs 0% NCT02969018
- 0% vs 0% NCT02969018
- 0% vs 0% NCT02969018
- 0% vs 0% NCT02969018
- Soficitinib (ICP-332)
- —Not reported
PASI 100
- brepocitinib
- —Not reported
- Soficitinib (ICP-332)
- —Not reported
sPGA 0/1
- brepocitinib
- 11.4% vs 8.2%+3.2 vs placeboNCT03850483
62 other results
- 8.6% vs 8.2% NCT03850483
- 14.3% vs 8.2% NCT03850483
- 16.2% vs 8.2% NCT03850483
- 14.7% vs 8.2% NCT03850483
- 11.8% vs 8.2% NCT03850483
- 16.2% vs 8.2% NCT03850483
- 13.5% vs 6.3% NCT03850483
- 5.6% vs 6.3% NCT03850483
- 8.6% vs 6.3% NCT03850483
- 13.5% vs 6.3% NCT03850483
- 8.8% vs 6.3% NCT03850483
- 11.8% vs 6.3% NCT03850483
- 8.1% vs 6.3% NCT03850483
- 10.3% vs 14.7% NCT03850483
- 15.4% vs 14.7% NCT03850483
- 10.3% vs 14.7% NCT03850483
- 21.4% vs 14.7% NCT03850483
- 20.8% vs 14.7% NCT03850483
- 27.6% vs 14.7% NCT03850483
- 17.9% vs 14.7% NCT03850483
- 5.4% vs 16.3% NCT03850483
- 8.1% vs 16.3% NCT03850483
- 8.3% vs 16.3% NCT03850483
- 16.2% vs 16.3% NCT03850483
- 16.7% vs 16.3% NCT03850483
- 8.6% vs 16.3% NCT03850483
- 13.2% vs 16.3% NCT03850483
- 5.4% vs 6.1% NCT03850483
- 5.4% vs 6.1% NCT03850483
- 2.8% vs 6.1% NCT03850483
- 10.8% vs 6.1% NCT03850483
- 13.9% vs 6.1% NCT03850483
- 5.7% vs 6.1% NCT03850483
- 18.4% vs 6.1% NCT03850483
- 5.4% vs 8.2% NCT03850483
- 2.7% vs 8.2% NCT03850483
- 8.3% vs 8.2% NCT03850483
- 13.5% vs 8.2% NCT03850483
- 8.3% vs 8.2% NCT03850483
- 5.7% vs 8.2% NCT03850483
- 13.2% vs 8.2% NCT03850483
- 5.4% vs 8.2% NCT03850483
- 0% vs 8.2% NCT03850483
- 5.6% vs 8.2% NCT03850483
- 5.4% vs 8.2% NCT03850483
- 8.3% vs 8.2% NCT03850483
- 11.4% vs 8.2% NCT03850483
- 21.1% vs 8.2% NCT03850483
- 0% vs 2% NCT03850483
- 0% vs 2% NCT03850483
- 2.8% vs 2% NCT03850483
- 2.7% vs 2% NCT03850483
- 0% vs 2% NCT03850483
- 5.7% vs 2% NCT03850483
- 10.5% vs 2% NCT03850483
- 2.7% vs 0% NCT03850483
- 2.7% vs 0% NCT03850483
- 0% vs 0% NCT03850483
- 0% vs 0% NCT03850483
- 0% vs 0% NCT03850483
- 5.7% vs 0% NCT03850483
- 5.3% vs 0% NCT03850483
- Soficitinib (ICP-332)
- —Not reported
DLQI, change
- brepocitinib
- —Not reported
- Soficitinib (ICP-332)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Soficitinib (ICP-332): no structured comparison results are available for Psoriasis.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. brepocitinib: 4 of 4 rows · Soficitinib (ICP-332): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | brepocitinib |
|---|---|
| Dropout rate | 16%60 mg Once Daily (QD) Followed by 30 mg QDa NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2 show 29 more results27.6%60 mg QD Followed by 10 mg QD NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2 23.1%60 mg QD Followed by 100 mg Once Weekly (QW) NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2 20%60 mg QD Followed by Placebo NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2 6.9%30 mg QD NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2 32%30 mg QD Followed by 10 mg QD NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2 26.7%30 mg QD Followed by 100 mg QW NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2 —200 mg single dose NCT02310750 · Phase 1 —175 mg once daily NCT02310750 · Phase 1 —100 mg NCT02310750 · Phase 1 —100 mg once daily NCT02310750 · Phase 1 —100 mg single dose NCT02310750 · Phase 1 —100 mg solution fasted NCT02310750 · Phase 1 —100 mg tablet fasted NCT02310750 · Phase 1 —100 mg tablet fed NCT02310750 · Phase 1 —50 mg twice daily NCT02310750 · Phase 1 —30 mg NCT02310750 · Phase 1 —30 mg once daily NCT02310750 · Phase 1 —30 mg single dose NCT02310750 · Phase 1 —10 mg once daily NCT02310750 · Phase 1 —10 mg single dose NCT02310750 · Phase 1 0%3 mg single dose NCT02310750 · Phase 1 14.3%1 mg single dose NCT02310750 · Phase 1 —0.1% QD NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2 —0.3% BID NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2 —0.3% QD NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2 —1.0% BID NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2 —1.0% QD NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2 —3.0% BID NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2 —3.0% QD NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2 |
| Discontinued due to AEs | 8%60 mg Once Daily (QD) Followed by 30 mg QDa NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2 show 29 more results13.8%60 mg QD Followed by 10 mg QD NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2 3.8%60 mg QD Followed by 100 mg Once Weekly (QW) NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2 8%60 mg QD Followed by Placebo NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2 0%30 mg QD NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2 4%30 mg QD Followed by 10 mg QD NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2 6.7%30 mg QD Followed by 100 mg QW NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2 —200 mg single dose NCT02310750 · Phase 1 —175 mg once daily NCT02310750 · Phase 1 —100 mg NCT02310750 · Phase 1 —100 mg once daily NCT02310750 · Phase 1 —100 mg single dose NCT02310750 · Phase 1 —100 mg solution fasted NCT02310750 · Phase 1 —100 mg tablet fasted NCT02310750 · Phase 1 —100 mg tablet fed NCT02310750 · Phase 1 —50 mg twice daily NCT02310750 · Phase 1 —30 mg NCT02310750 · Phase 1 —30 mg once daily NCT02310750 · Phase 1 —30 mg single dose NCT02310750 · Phase 1 —10 mg once daily NCT02310750 · Phase 1 —10 mg single dose NCT02310750 · Phase 1 —3 mg single dose NCT02310750 · Phase 1 —1 mg single dose NCT02310750 · Phase 1 —0.1% QD NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2 —0.3% BID NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2 —0.3% QD NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2 —1.0% BID NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2 —1.0% QD NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2 —3.0% BID NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2 —3.0% QD NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2 |
| Serious AEs | 8%60 mg Once Daily (QD) Followed by 30 mg QDa NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2 show 29 more results3.4%60 mg QD Followed by 10 mg QD NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2 3.8%60 mg QD Followed by 100 mg Once Weekly (QW) NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2 4%60 mg QD Followed by Placebo NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2 0%30 mg QD NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2 0%30 mg QD Followed by 10 mg QD NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2 0%30 mg QD Followed by 100 mg QW NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2 0%200 mg single dose NCT02310750 · Phase 1 0%175 mg once daily NCT02310750 · Phase 1 0%100 mg NCT02310750 · Phase 1 0%100 mg once daily NCT02310750 · Phase 1 0%100 mg single dose NCT02310750 · Phase 1 0%100 mg solution fasted NCT02310750 · Phase 1 0%100 mg tablet fasted NCT02310750 · Phase 1 0%100 mg tablet fed NCT02310750 · Phase 1 0%50 mg twice daily NCT02310750 · Phase 1 0%30 mg NCT02310750 · Phase 1 0%30 mg once daily NCT02310750 · Phase 1 0%30 mg single dose NCT02310750 · Phase 1 0%10 mg once daily NCT02310750 · Phase 1 0%10 mg single dose NCT02310750 · Phase 1 0%3 mg single dose NCT02310750 · Phase 1 0%1 mg single dose NCT02310750 · Phase 1 0%0.1% QD NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2 2.8%0.3% BID NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2 0%0.3% QD NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2 5.6%1.0% BID NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2 2.8%1.0% QD NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2 0%3.0% BID NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2 0%3.0% QD NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2 |
| Most frequent reported AEs | 60 mg Once Daily (QD) Followed by 30 mg QDa nasopharyngitis 16% (placebo 13%) upper respiratory tract infection 8% (placebo 4.3%) arthralgia 4% (placebo 4.3%) NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2 show 29 more results60 mg QD Followed by 10 mg QD nasopharyngitis 10.3% (placebo 13%) acne 6.9% (placebo 0%) arthralgia 6.9% (placebo 4.3%) NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2 60 mg QD Followed by 100 mg Once Weekly (QW) upper respiratory tract infection 19.2% (placebo 4.3%) headache 11.5% (placebo 4.3%) nasopharyngitis 11.5% (placebo 13%) NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2 60 mg QD Followed by Placebo headache 12% (placebo 4.3%) nasopharyngitis 12% (placebo 13%) pruritus 12% (placebo 0%) NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2 30 mg QD nasopharyngitis 17.2% (placebo 13%) headache 13.8% (placebo 4.3%) back pain 6.9% (placebo 8.7%) NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2 30 mg QD Followed by 10 mg QD nasopharyngitis 24% (placebo 13%) back pain 8% (placebo 8.7%) ligament sprain 8% (placebo 0%) NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2 30 mg QD Followed by 100 mg QW nasopharyngitis 13.3% (placebo 13%) diarrhoea 10% (placebo 4.3%) upper respiratory tract infection 10% (placebo 4.3%) NCT02969018 · Phase 2 · monotherapy · Psoriasis · phase 2 200 mg single dose blood creatinine increased 12.5% (placebo 11.1%) headache 12.5% (placebo 0%) abnormal dreams 0% (placebo 0%) NCT02310750 · Phase 1 175 mg once daily blood creatinine increased 66.7% (placebo 11.1%) constipation 16.7% (placebo 33.3%) neutropenia 16.7% (placebo 0%) NCT02310750 · Phase 1 100 mg blood creatinine increased 85.7% (placebo 11.1%) flushing 14.3% (placebo 0%) headache 14.3% (placebo 0%) NCT02310750 · Phase 1 100 mg once daily blood creatinine increased 16.7% (placebo 11.1%) headache 16.7% (placebo 0%) upper respiratory tract infection 16.7% (placebo 0%) NCT02310750 · Phase 1 100 mg single dose blood creatinine increased 12.5% (placebo 11.1%) constipation 12.5% (placebo 33.3%) dizziness 12.5% (placebo 0%) NCT02310750 · Phase 1 100 mg solution fasted headache 8.3% (placebo 0%) nausea 8.3% (placebo 0%) abnormal dreams 0% (placebo 0%) NCT02310750 · Phase 1 100 mg tablet fasted contusion 8.3% (placebo 0%) abnormal dreams 0% (placebo 0%) blood creatinine increased 0% (placebo 11.1%) NCT02310750 · Phase 1 100 mg tablet fed abnormal dreams 0% (placebo 0%) blood creatinine increased 0% (placebo 11.1%) constipation 0% (placebo 33.3%) NCT02310750 · Phase 1 50 mg twice daily blood creatinine increased 80% (placebo 11.1%) neutrophil count decreased 40% (placebo 0%) abnormal dreams 0% (placebo 0%) NCT02310750 · Phase 1 30 mg blood creatinine increased 50% (placebo 11.1%) constipation 21.4% (placebo 33.3%) abnormal dreams 7.1% (placebo 0%) NCT02310750 · Phase 1 30 mg once daily blood creatinine increased 25% (placebo 11.1%) presyncope 25% (placebo 0%) abnormal dreams 0% (placebo 0%) NCT02310750 · Phase 1 30 mg single dose haematoma 16.7% (placebo 0%) abnormal dreams 0% (placebo 0%) blood creatinine increased 0% (placebo 11.1%) NCT02310750 · Phase 1 10 mg once daily blood creatinine increased 20% (placebo 11.1%) syncope 20% (placebo 0%) upper respiratory tract infection 20% (placebo 0%) NCT02310750 · Phase 1 10 mg single dose abnormal dreams 0% (placebo 0%) blood creatinine increased 0% (placebo 11.1%) constipation 0% (placebo 33.3%) NCT02310750 · Phase 1 3 mg single dose headache 16.7% (placebo 0%) abnormal dreams 0% (placebo 0%) blood creatinine increased 0% (placebo 11.1%) NCT02310750 · Phase 1 1 mg single dose urine flow decreased 14.3% (placebo 0%) abnormal dreams 0% (placebo 0%) blood creatinine increased 0% (placebo 11.1%) NCT02310750 · Phase 1 0.1% QD nasopharyngitis 8.1% (placebo 6.1%) headache 5.4% (placebo 0%) upper respiratory tract infection 5.4% (placebo 4.1%) NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2 0.3% BID cough 5.6% (placebo 4.1%) headache 2.8% (placebo 0%) nasopharyngitis 2.8% (placebo 6.1%) NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2 0.3% QD cough 5.4% (placebo 4.1%) rhinitis 5.4% (placebo 2%) hypertension 2.7% (placebo 4.1%) NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2 1.0% BID nasopharyngitis 19.4% (placebo 6.1%) cough 5.6% (placebo 4.1%) hypertension 5.6% (placebo 4.1%) NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2 1.0% QD nasopharyngitis 16.7% (placebo 6.1%) blood creatine phosphokinase increased 5.6% (placebo 0%) cough 2.8% (placebo 4.1%) NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2 3.0% BID hypertension 2.6% (placebo 4.1%) pruritus 2.6% (placebo 2%) upper respiratory tract infection 2.6% (placebo 4.1%) NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2 3.0% QD nasopharyngitis 8.1% (placebo 6.1%) hypertension 5.4% (placebo 4.1%) upper respiratory tract infection 5.4% (placebo 4.1%) NCT03850483 · Phase 2 · registry result, not featured evidence · monotherapy · Psoriasis · phase 2 |
Notes
- aPopulation comparability has not been reviewed for 16 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
brepocitinib
show 64 more results
show 125 more results
show 62 more results
show 62 more results
show 125 more results
show 62 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: brepocitinib's landscape · Soficitinib (ICP-332)'s landscape